Previous meta-analysis pooled safety data from randomized controlled trials and results indicated that second-generation EGFR-TKI afatinib and dacomitinib might have a greater probability of grade 3 or higher AEs and third-generation EGFR-TKI osimertinib has mild toxicity profile.32,33 For specific AEs, among the different EGFR-TKIs, dacomitinib was associated with the highest risk of paronychia and dry skin and diarrhea was also another AE that needed to be noted. Here, EGFR is linked to paronychia.